Last reviewed 2026-05-19 · How we verify

Bevacizumab-EU (bevacizumab-eu)

Bevacizumab-EU (generic name: bevacizumab-eu) is a 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we Monoclonal antibody drug developed by Pfizer Inc.. It is currently in discontinued development.

15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we

Bevacizumab-EU is an antibody that inhibits vascular endothelial growth factor A, a protein involved in the formation of new blood vessels. It is used as a first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.

At a glance

Mechanism of action

Bevacizumab works by targeting a specific protein called VEGF (vascular endothelial growth factor) that tumors produce to stimulate the growth of new blood vessels. Tumors need their own blood supply to grow beyond a certain size and to spread to other parts of the body. By binding to and neutralizing VEGF, bevacizumab prevents this new vessel formation, essentially starving the tumor of nutrients and oxygen. This approach is different from traditional chemotherapy because it doesn't directly kill cancer cells. Instead, it cuts off the tumor's life support system. By limiting blood vessel growth around the cancer, bevacizumab can slow tumor progression and improve survival outcomes. The drug is given as an intravenous infusion, often in combination with chemotherapy or other cancer treatments. Because bevacizumab targets a process that tumors depend on rather than attacking the cancer cells themselves, it can be effective across multiple cancer types where VEGF-driven angiogenesis (blood vessel formation) plays an important role. This mechanism also explains why bevacizumab must be used carefully, as blocking blood vessel formation can affect normal tissues and organs throughout the body.

Approved indications

No approved indications tracked.

Pipeline indications

• Advanced Non-squamous NSCLC — discontinued

Common side effects

No common side effects on file.

Key clinical trials

• To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (PHASE3)
• A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers (PHASE1)
• To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects (PHASE1)
• A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC (PHASE3)
• Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
• TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer (PHASE3)
• Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers (PHASE1)
• A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bevacizumab-EU CI brief — competitive landscape report
• Bevacizumab-EU updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI

Frequently asked questions about Bevacizumab-EU

Related

• Drug class: All 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we drugs
• Manufacturer: Pfizer Inc. — full pipeline
• Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing